Fortrea (FTRE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Election of three directors: Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh, with board recommending a vote for each.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory (non-binding) approval of named executive officer compensation.
Other business may be addressed as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fortrea
- Raised 2026 guidance after strong Q2 execution, improved profitability, and robust backlog.FTRE
Q2 2026 - Strong book-to-bill, commercial transformation, and debt reduction highlight strategic progress.FTRE
Jefferies 2024 Global Healthcare Conference - All director, auditor, and Say-on-Pay proposals were approved by requisite vote.FTRE
AGM 2026 - Demand, bookings, and technology integration are driving recovery and positioning for future growth.FTRE
Jefferies Global Healthcare Conference 2026 - Adjusted EBITDA rose to $47M as net loss narrowed and guidance was reaffirmed.FTRE
Q1 2026 - Annual meeting covers director elections, auditor ratification, and executive pay, with strong governance focus.FTRE
Proxy filing - 2025 results met guidance; 2026 targets margin growth and stability despite goodwill impairment.FTRE
Q4 2025 - Driving clinical trial modernization and margin expansion in a $40B global market.FTRE
44th Annual J.P. Morgan Healthcare Conference - Q3 revenue up 3.9%, net loss narrowed, but goodwill impairment led to a large YTD loss.FTRE
Q3 2025